Moderna Inc. (MRNA) 10-K Red Flags
Risk signals extracted deterministically from Moderna Inc.’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.
Detected red flags (6)
- Inventory buildup exceeds sales growth: Inventory grew +30.8% vs revenue -39.9%. Excess inventory may signal weakening demand, potential write-downs, or supply chain overcommitment. Watch gross margin for discounting impact.
- Endogenous analysis: 1 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- Revenue declined **+39.9%** YoY to $1.94B.
- 5-year revenue CAGR **-36.3%**; 10y CAGR +28.3%.
Filings & ownership
- Latest annual report (10-K) filed Feb 20, 2026.
- Latest quarterly report (10-Q) filed Jul 31, 2026.
- 14 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 6 sell transactions — net selling $35.1M.
- ~10,000+ recent 13F-HR filings reference Moderna Inc.; broad institutional reporting.
- Recent filers include Theleme Partners LLP, Theleme Partners LLP, Theleme Partners LLP.
- 20 recent 13G passive institutional ownership notices.
Full MRNA analyst report
Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.
View full report →Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.